Mouse Anti-LIMD1 Recombinant Antibody (A904) (CBMAB-AP4300LY)

Li, W. H., Huang, K., Wen, F. B., Cui, G. H., Guo, H. Z., & Zhao, S. (2022). PLOD3 regulates the expression of YAP1 to affect the progression of non-small cell lung cancer via the PKCδ/CDK1/LIMD1 signaling pathway. Laboratory Investigation, 102(4), 440-451.

Wang, Y., Zhang, C., Yang, W., Shao, S., Xu, X., Sun, Y., ... & Wu, C. (2021). LIMD1 phase separation contributes to cellular mechanics and durotaxis by regulating focal adhesion dynamics in response to force. Developmental Cell, 56(9), 1313-1325.

Landry, N. M., Rattan, S. G., Filomeno, K. L., Meier, T. W., Meier, S. C., Foran, S. J., ... & Dixon, I. M. (2021). SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation. Basic Research in Cardiology, 116, 1-27.

Zeng, X., Wang, H., He, D., Jia, W., & Ma, R. (2020). LIMD1 increases the sensitivity of lung adenocarcinoma cells to cisplatin via the GADD45α/p38 MAPK signaling pathway. Frontiers in Oncology, 10, 969.

Pan, J., Tang, Y., Liu, S., Li, L., Yu, B., Lu, Y., & Wang, Y. (2020). LIMD1‐AS1 suppressed non‐small cell lung cancer progression through stabilizing LIMD1 mRNA via hnRNP U. Cancer Medicine, 9(11), 3829-3839.

Zhou, J., Zhang, L., Zhou, W., Chen, Y., Cheng, Y., & Dong, J. (2019). LIMD 1 phosphorylation in mitosis is required for mitotic progression and its tumor‐suppressing activity. The FEBS Journal, 286(5), 963-974.

Wang, L., Howell, M. E., McPeak, B., Riggs, K., Kohne, C., Yohanon, J. U., ... & Ning, S. (2018). LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death. Oncotarget, 9(5), 6282.

Zhang, D., Li, S., Yu, W., Chen, C., Liu, T., Sun, Y., ... & Liu, L. (2018). LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1. Cancer Management and Research, 4349-4361.

Ibar, C., Kirichenko, E., Keepers, B., Enners, E., Fleisch, K., & Irvine, K. D. (2018). Tension-dependent regulation of mammalian Hippo signaling through LIMD1. Journal of Cell Science, 131(5), jcs214700.

Foxler, D. E., Bridge, K. S., Foster, J. G., Grevitt, P., Curry, S., Shah, K. M., ... & Sharp, T. V. (2018). A HIF–LIMD 1 negative feedback mechanism mitigates the pro‐tumorigenic effects of hypoxia. EMBO molecular medicine, 10(8), e8304.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols